Akebia corporate presentation
WebGreg Falesnik oversees all aspects of the firm’s investor relations activities. He plays an integral role in MZ’s consulting process; including institutional outreach, corporate … WebApr 7, 2024 · Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is...
Akebia corporate presentation
Did you know?
WebOct 21, 2024 · CAMBRIDGE, Mass., Oct. 21, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,... Webwww.slidescarnival.com
WebAkebia Therapeutics, Inc. 245 First Street, Suite 1400. Cambridge, MA 02142. Driving Directions. +1 617.871.2098 phone. +1 617.871.2099 fax. Contact Us. Our website uses … WebNov 16, 2024 · The Investor Relations website contains information about Akebia Therapeutics's business for stockholders, potential investors, and financial analysts.
Web2 days ago · Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2024 CAMBRIDGE, Mass. , Oct. 21, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ... 5 months ago - PRNewsWire WebOct 17, 2016 · Akebia AJ Gosselin, 617-844-6130 Manager, Corporate Communications [email protected] Release Summary Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week ...
WebMay 29, 2015 · Akebia's lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis ...
WebMar 13, 2024 · Akebia Therapeutics, Inc. (NASDAQ: AKBA) Q4 2024 Earnings Call Transcript March 9, 2024 Operator: Good day ladies and gentlemen. Thank you for … mini makery chesterWebWe are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat.Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science. mini maker wildflowers tutorialWebMar 30, 2024 · The Investor Relations website contains information about Akebia Therapeutics's business for stockholders, potential investors, and financial analysts. most profitable football clubsWebApr 10, 2024 · CAMBRIDGE - Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present posters at the National Kidney Foundation (NKF) Spring Clinical Meetings 2024 (SCM23), which will take place on … mini maker stitchery wildflowersWebNov 29, 2024 · The Investor Relations website contains information about Akebia Therapeutics's business for stockholders, potential investors, and financial analysts. ... Events & Presentations. April 11, 2024 at 10:00 AM EDT Special Meeting of Stockholders . ... Akebia is not associated with or sponsored by the trademark owners. mini maker warrior catsWebMar 9, 2024 · CAMBRIDGE, Mass., March 9, 2024 /PRNewswire/ — Akebia Therapeutics ®, Inc. ( Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full-year ended December 31, 2024 and provided business highlights. mini majesty of the seasWebAkebia Therapeutics ® and its associated logos are trademarks of Akebia and/or its affiliates. All other trademarks and registered trademarks, trade names and service … most profitable forex strategy